Collegium Pharmaceutical, Inc. (COLL)

Collegium Pharmaceutical Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	757.07	631.45	566.77	463.93	276.87	310.02
Revenue Growth (YoY)	26.34%	11.41%	22.17%	67.56%	-10.69%	4.49%
Cost of Revenue	92.61	83.53	79.72	118.19	59.07	69.5
Gross Profit	664.46	547.92	487.05	345.74	217.8	240.52
Selling, General & Admin	267.58	182.98	150.71	172.19	118.96	113.83
Research & Development	-	-	-	3.98	9.45	9.77
Amortization of Goodwill & Intangibles	221.89	165.3	145.76	131.47	67.18	60.68
Operating Expenses	489.47	348.29	296.47	307.64	195.59	184.28
Operating Income	174.99	199.63	190.58	38.11	22.21	56.23
Interest Expense	-85.67	-73.97	-83.34	-63.21	-21.01	-28.88
Interest & Investment Income	9.54	13.98	15.62	1.05	0.01	0.23
EBT Excluding Unusual Items	98.85	139.63	122.85	-24.06	1.2	27.58
Merger & Restructuring Charges	-17.62	-29.6	-15.12	-	-4.58	-
Asset Writedown	-	-	-	-4.79	-	-
Legal Settlements	-3.06	-	-8.5	-	-	-
Other Unusual Items	2.68	-11.47	-23.5	-	-	-
Pretax Income	80.85	98.57	75.73	-28.85	-3.37	27.58
Income Tax Expense	22.41	29.38	27.58	-3.85	-74.89	0.83
Net Income	58.44	69.19	48.16	-25	71.52	26.75
Net Income to Common	58.44	69.19	48.16	-25	71.52	26.75
Net Income Growth	-34.03%	43.68%	-	-	167.33%	-
Shares Outstanding (Basic)	32	32	34	34	35	34
Shares Outstanding (Diluted)	40	40	42	34	41	35
Shares Change (YoY)	-13.26%	-3.26%	23.53%	-17.58%	16.77%	5.07%
EPS (Basic)	1.84	2.14	1.43	-0.74	2.05	0.78
EPS (Diluted)	1.63	1.86	1.29	-0.74	1.86	0.76
EPS Growth	-24.84%	43.56%	-	-	144.25%	-
Free Cash Flow	289.3	203.33	274.29	122.61	101.61	88.4
Free Cash Flow Per Share	7.29	5.03	6.56	3.62	2.48	2.52
Gross Margin	87.77%	86.77%	85.93%	74.52%	78.66%	77.58%
Operating Margin	23.11%	31.61%	33.63%	8.21%	8.02%	18.14%
Profit Margin	7.72%	10.96%	8.50%	-5.39%	25.83%	8.63%
Free Cash Flow Margin	38.21%	32.20%	48.39%	26.43%	36.70%	28.51%
EBITDA	401.18	368.79	339.83	172.26	91.12	117.78
EBITDA Margin	52.99%	58.40%	59.96%	37.13%	32.91%	37.99%
D&A For EBITDA	226.19	169.16	149.26	134.15	68.92	61.55
EBIT	174.99	199.63	190.58	38.11	22.21	56.23
EBIT Margin	23.11%	31.61%	33.63%	8.21%	8.02%	18.14%
Effective Tax Rate	27.72%	29.80%	36.41%	-	-	3.01%
Advertising Expenses	-	10.66	7.41	11.74	4.19	5.37

Updated Nov 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q